DME (psychedelic)
Names | |
---|---|
Preferred IUPAC name 2-Amino-1-(3,4-dimethoxyphenyl)ethan-1-ol | |
Other names 3,4-Dimethoxy-beta-hydroxyphenethylamine 3,4-Dimethoxy-1-ethyl-(beta-hydroxy)amine | |
Identifiers | |
3D model (JSmol) |
|
ChemSpider | |
PubChem CID |
|
UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
Properties | |
C10H15NO3 | |
Molar mass | 197.234 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
DME (3,4-dimethoxy-beta-hydroxyphenethylamine) is a lesser-known psychedelic drug. It is the beta-hydroxy derivative of 3,4-dimethoxyphenethylamine. DME was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 115 mg, and the duration unknown. DME produces few to no effects.[1] Very little data exists about the pharmacological properties, metabolism, and toxicity of DME.
Legality
United Kingdom
This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]
See also
References
- ^ DME Entry in PiHKAL
- ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Retrieved 12 March 2014.